An article reported that the BRAFV600E mutation, which occurs in ~45% of patients with PTC, affects HIF1-α expression in thyroid cancers by regulating hypoxia and the BRAFV600E-mediated signaling pathway [48]. Here, HIF1A is linked to thyroid cancer.